Benralizumab: A Unique IL-5 Inhibitor for Severe Asthma

Journal of Asthma and Allergy - New Zealand
doi 10.2147/jaa.s78049
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Benralizumab for the Treatment of Severe Eosinophilic Asthma

Prescriber
Pharmacology
2018English

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2020English

The Clinical Profile of Benralizumab in the Management of Severe Eosinophilic Asthma

Therapeutic Advances in Respiratory Disease
PulmonaryRespiratory MedicinePharmacology
2016English

Daily Patient-Reported Health Status Assessment Improvements With Benralizumab for Patients With Severe, Uncontrolled Eosinophilic Asthma

Journal of Asthma and Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2019English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2020English

P68 Asthma Symptom Improvements With Benralizumab Are Associated With Improvements in Activity Functions and Quality of Life for Patients With Severe, Uncontrolled Asthma: Results of Pooled Phase Iii Benralizumab Studies

2017English

Benralizumab in the Treatment of Severe Asthma: Design, Development and Potential Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Anti-Interleukin-5 Therapy in Severe Asthma

European Respiratory Review
PulmonaryRespiratory Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy